# EDGAR Filing Document

**Accession Number:** 0001533998
**File Stem:** 0001104659-25-124834
**Filing Date:** 2025-12
**Character Count:** 10421
**Document Hash:** 7033d0dea70d37c0184fefb56c9bea06
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-124834.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001104659-25-124834

**CONFORMED SUBMISSION TYPE**: S-3/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DarioHealth Corp.
- **CENTRAL INDEX KEY:** 0001533998
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 452973162
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290969
- **FILM NUMBER:** 251609157

**BUSINESS ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 972-4-770-6377

**MAIL ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LabStyle Innovations Corp.
- **DATE OF NAME CHANGE:** 20111101

**As filed with the Securities and Exchange Commission on December 29, 2025**

**Registration No. 333-290969**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**AMENDMENT NO. 1 TO**

**FORM S-3/A**

**REGISTRATION STATEMENT**

**UNDER THE SECURITIES ACT OF 1933**

**DARIOHEALTH CORP.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Delaware**<br> **(State or other jurisdiction**<br> **of incorporation or organization)** | **45-2973162**<br> **(I.R.S. Employer**<br> **Identification No.)** |

---

**322 W. 57th St. #33B**

**New York, New York 10019**

**Telephone: (972) 4-770-6377**

**(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)**

**Mr. Erez Raphael**

**Chief Executive Officer**

**DarioHealth Corp.**

**322 W. 57th St. #33B**

**New York, New York 10019**

**Telephone: (972) 4-770-6377**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

***Copies to:***

**Oded Har-Even, Esq.**

**Ron Ben-Bassat, Esq.**

**Sullivan & Worcester LLP**

**1251 Avenue of the Americas**

**New York, New York 10020**

**Telephone: (212) 660-5000**

**Facsimile: (212) 660-3001**

**Approximate date of commencement of proposed sale to the public:** From time to time after the effective date of this registration statement, as determined by market and other conditions.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ◻

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ⌧

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ◻

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ◻

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ◻

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer: ◻ Accelerated filer: ◻ <br> Non-accelerated filer: ⌧ Smaller reporting company: ⌧ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ◻

**THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.**

**EXPLANATORY NOTE**

This Pre-Effective Amendment No.1 (the "Amendment") is being filed to amend the Registration Statement on Form S-3 (File No. 333-290969), originally filed by the registrant on October 20, 2025 (the "Registration Statement"). The sole purpose of this Amendment is to file an updated Exhibit 23.1 and in connection therewith to amend and restate the exhibit index set forth in Part II of the Registration Statemen. Accordingly, this Amendment consists only of the cover page of the Registration Statement, this Explanatory Note, the Exhibit Index to the Registration Statement, the signature pages and Exhibit 23.1 filed herewith. This Amendment does not modify any provision of the prospectus contained in Part I or the balance of Part II of the Registration Statement.

**Item 16. Exhibits**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [4.1^](https://www.sec.gov/Archives/edgar/data/1533998/000110465925093431/tm2526967d1_ex4-1.htm) | [Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 25, 2025)](https://www.sec.gov/Archives/edgar/data/1533998/000110465925093431/tm2526967d1_ex4-1.htm) |
| [5.1^](https://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_ex5-1.htm) | [Opinion of Sullivan & Worcester LLP](https://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_ex5-1.htm) |
| [10.1^](https://www.sec.gov/Archives/edgar/data/1533998/000110465925093431/tm2526967d1_ex10-1.htm) | [Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 25, 2025)](https://www.sec.gov/Archives/edgar/data/1533998/000110465925093431/tm2526967d1_ex10-1.htm) |
| [23.1\*](tm2534209d1_ex23-1.htm) | [Consent of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global](tm2534209d1_ex23-1.htm) |
| [23.2\*](http://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_ex5-1.htm) | [Consent of Sullivan & Worcester LLP (included in Exhibit 5.1)](http://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_ex5-1.htm) |
| [24.1^](https://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_s3.htm#s3_013) | [Power of Attorney](https://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_s3.htm#s3_013) |
| [107^](https://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_exfilingfees.htm) | [Filing Fee Table](https://www.sec.gov/Archives/edgar/data/1533998/000110465925100809/tm2529064d1_exfilingfees.htm) |

---

\* Filed herewith

^ Previously filed

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Caesarea, Israel on the 29th day of December 2025.

---

| | |
|:---|:---|
| **DARIOHEALTH CORP.** | **DARIOHEALTH CORP.** |
| By: | /s/ Erez Raphael |
| Name: | Erez Raphael |
| Title: | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Person** | **Capacity** | **Date** |
| /s/ Erez Raphael | Chief Executive Officer | December 29, 2025 |
| Erez Raphael | (Principal Executive Officer) |  |
| /s/ Chen Franco-Yehuda | Chief Financial Officer, Secretary and Treasurer | December 29, 2025 |
| Chen Franco-Yehuda | (Principal Financial and Accounting Officer) |  |
| \* | Chairman of the Board of Directors | December 29, 2025 |
| Yoav Shaked |  |  |
| \* | Director | December 29, 2025 |
| Lawrence Leisure |  |  |
| \* | Director | December 29, 2025 |
| Hila Karah |  |  |
| \* | Director | December 29, 2025 |
| Dennis Matheis |  |  |
| \* | Director | December 29, 2025 |
| Dennis M. McGrath |  |  |
| \* | Director | December 29, 2025 |
| Adam Stern |  |  |

---

---

| |
|:---|
| *\* /s/ Erez Raphael* |
| Erez Raphael |
| Attorney-in-fact |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form S-3) and related Prospectus of DarioHealth Corp. for the registration of common stock and to the incorporation by reference therein of our report dated March 10, 2025, with respect to the consolidated financial statements of DarioHealth Corp. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

---

| | |
|:---|:---|
| Tel-Aviv, Israel | /s/ KOST FORER GABBAY & KASIERER<br> KOST FORER GABBAY & KASIERER |
| December 29, 2025 | A Member of EY Global |

---